119 related articles for article (PubMed ID: 33910221)
1. Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Lehmer L; Choi F; Kraus C; Shiu J; de Feraudy S; Elsensohn A
Am J Dermatopathol; 2021 May; 43(5):321-330. PubMed ID: 33910221
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.
Choi FD; Kraus CN; Elsensohn AN; Carley SK; Lehmer LM; Nguyen RT; Linden KG; Shiu J
J Am Acad Dermatol; 2020 Feb; 82(2):440-459. PubMed ID: 31163235
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
Guénolé M; Bénigni P; Bourbonne V; Lucia F; Legoupil D; Pradier O; Misery L; Uguen A; Schick U
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2569-2578. PubMed ID: 34115240
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Aghajani M; Graham S; McCafferty C; Shaheed CA; Roberts T; DeSouza P; Yang T; Niles N
Thyroid; 2018 Mar; 28(3):349-361. PubMed ID: 29455638
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
9. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
Liu HQ; Zou BQ; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
[No Abstract] [Full Text] [Related]
12. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
García-Díez I; Hernández-Ruiz E; Andrades E; Gimeno J; Ferrándiz-Pulido C; Yébenes M; García-Patos V; Pujol RM; Hernández-Muñoz I; Toll A
Am J Dermatopathol; 2018 Sep; 40(9):647-654. PubMed ID: 29742559
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
15. Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma.
Yülek Ö; Batur Ş; Özcan K; Yol C; Aydın Ülgen Ö
Bosn J Basic Med Sci; 2022 Oct; 22(6):894-900. PubMed ID: 35801411
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas.
Wu S; Slater NA; Sayed CJ; Googe PB
J Cutan Pathol; 2020 Oct; 47(10):882-887. PubMed ID: 32279340
[TBL] [Abstract][Full Text] [Related]
17. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Omenai SA; Ajani MA; Okolo CA
PLoS One; 2022; 17(2):e0263615. PubMed ID: 35139126
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
Stovgaard ES; Dyhl-Polk A; Roslind A; Balslev E; Nielsen D
Breast Cancer Res Treat; 2019 Apr; 174(3):571-584. PubMed ID: 30627961
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.
Cavalieri S; Perrone F; Milione M; Bianco A; Alfieri S; Locati LD; Bergamini C; Resteghini C; Galbiati D; Platini F; Licitra L; Bossi P
Oncology; 2019; 97(2):112-118. PubMed ID: 31112973
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
